Novartis and Orion submit application to U.S. Food and Drug Administration for approval of a new product for Parkinson's Disease
Combination Product Contains Widely Used Parkinson's Therapies
28-Aug-2002 -
East Hanover, NJ, August 26, 2002 – Novartis Pharmaceuticals Corporation and Orion Pharma announced today the filing of a New Drug Application with the U.S. Food and Drug Administration to market the first triple combination product for the treatment of Parkinson's Disease. This new product ...
clinical trials
dopamine
dosing
+3